35 results about "Interferon inducer" patented technology

The present invention relates to a heterocyclic compound of the following general formula (I):wherein X is sulfur atom, oxygen atom or -NR3- (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R1 via the nitrogen atom),R1 is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, andR2 is hydrogen atom, halogen atom etc.;or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.

The present invention relates to compounds of formula (I):

wherein;

• • R¹ represents hydrogen or C_1-3alkyl;
  • n is an integer having a value of 1 to 5;
  • X represents O or NH;
  • Y represents C or N;

or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.

The invention discloses a herpes zoster vaccine, and a preparation method and an application thereof, and belongs to the field of vaccines. The herpes zoster vaccine is provided against the problem ofhigh safety risk of existing herpes zoster vaccines, and an adjuvant used by the herpes zoster vaccine is Poly (I:C). The Poly(I:C) is called polyinosinic-polycytidylic acid for short, and is double-stranded RNA, and the safety of the Poly(I:C) is confirmed during large-scale clinical application. The Poly(I:C) is a high-efficiency interferon inducer, can produce an immune reaction like viral infection in vivo, and can induce CD4<+> and CD8<+> T cells and enhance cellular and humoral immune responses.

The invention provides a transgene pig for preparing an animal model for human diseases and a culturing method thereof. An inducible expression Cre recombinase expression vector pET28a-Mxl-Cre-BGHpolyA-FRT2neoR is constructed by a genetic engineering method, and can express Cre recombinase after the expression vector is induced by interferon inducer poly IC (poly I:C) so as to be used for knocking out a target gene; porcine mechanocyte capable of inducibly expressing the Cre recmbinase can be screened through technology of cell transfection and cell screening; and the pig is cloned by the technology of somatic cell nuclear transplantation. The cloned pig can be used for preparing the animal model for knocking out genes of human diseases.

The invention discloses a cat interferon omega, and a preparation method and antiviral application thereof. The amino acid sequence of the cat interferon omega is as shown in SEQ ID NO. 2. Preferably,a nucleotide sequence encoding the cat interferon omega is as shown in SEQ ID NO. 1. In addition, the invention also discloses the method for preparing the cat interferon omega and the application ofthe cat interferon omega to preparation of antiviral drugs. According to the invention, the manner of combined stimulation by a virus (cat intestinal coronavirus) and an interferon inducer (poly I: C) is employed for stimulating the body of a pet cat so as to induce the expression of a cat interferon gene; and then, PCR amplification is carried out to obtain a cat interferon omega gene. The results of cell tests show that the cat interferon omega obtained in the invention has obvious antiviral activity and is superior to existing known cat interferons. The invention lays a foundation for further research, development and application of cat interferon products.

The invention relates to a veterinary interferon inducer. The veterinary interferon inducer is prepared from the following components: a sodium chloride-phosphate buffer solution with the pH value of 7.2, a 10-80g/L calcium chloride aqueous solution, a 0.1-5g/L chitosan hydrochloride solution, polyinosinic acid and polycytidysic acid. The invention further provides a preparation method of the veterinary interferon inducer. The veterinary interferon inducer provided by the invention is few in side reaction, low in irritation and high in safety, and the preparation method can avoid precipitates generated by calcium chloride and other components.

The invention discloses application of reovirus dsRNA in preparation of a medical endogenous interferon inducer. Reov-dsRNAEnII is prepared by using purified reovirus dsRNA as a material, directly acts on a body to induce and generate various endogenous interferons and endows a human body with functions of virus resistance, tumor resistance and constitution enhancement. The reovirus has the advantages that: (A) the reovirus cannot cause remarkable diseases to a human body, does not have tumor derivation, and is remarkably safe; (B) the interferon generated by inducing the human body is complete in types and high in in-vivo concentration, is highly in accordance with the species specificity in human-sourced virus and eukaryotic molecules, does not have immunological rejection or dependence, and has extremely strong bioactivity and pharmacologic effect and high drug effect on a human body; (C) the dsRNA biomaterial is natural and green, and eco-friendly; (D) the resource is endlessly renewable, and is inexhaustible; (E) the special virus dsRNA material can realize high-throughput proliferation, extraction and modern preparation, and is low in cost.

The invention discloses a preparation method of endogenous interferon inducer injection and nanometer microencapsulation solution, relating to a pharmaceutical composition for treating and curing breeding animal viral infection by improving the inducement level of endogenous interferon. The invention uses endogenous interferon induction technology, avoids the defects of strong specificity of self species of interferon preparation, is convenient to apply in production and practice by drug administration in various modes and has the characteristics of low onset dose and the like, and degradation products can directly enter an animal body metabolic pool to continue metabolizing. In addition, the invention has an important meaning for effectively controlling raised animal viral infection and lowering drug residue harm.

The invention provides a pig interferon inducer. The active components of the pig interferon inducer consist of purified pig alpha-interferon, ginseng polysaccharide, ginsenoside, hydroxymethyl tuckahoe polysaccharide and polysaccharide-peptide. By weighing up the active components and adding with glycerin and gelatin for fully mixing, a suspending liquid is prepared, and the suspending liquid needs to be stored in light-shading places. For porcine reproductive respiratory syndrome, hog cholera and pseudorabies, the effective prevention rate of the pig interferon inducer provided by the invention is more than 70 percent. The invention provides a veterinary medicine which is safe, effective and low-priced, and can prevent diseases, and the cells are induced to generate the interferon by stimulating an animal body, so that the veterinary medicine has various biological activities of resisting virus in the broad spectrum, improving body immunity and the like, and the aims of preventing and curing viral diseases are achieved. The pig interferon inducer has the advantages of solving the problems of high production cost and inconvenient use existing in the leukocyte interferon and the recombination interferon of the pig, along with simple production process, low production cost and convenient popularization.

The invention discloses a composite interferon inducer for pigs. The composite interferon inducer consists of the following components in percentage by weight: 5 to 50 percent of echinacea extract, 10 to 50 percent of hypericin and 5 to 50 percent of yeast nucleotide. The composite interferon inducer for the pigs can greatly improve the interferon level in serum of piglets, so the composite interferon inducer can well induce the piglets to generate I-type interferon.

The invention discloses a preparation method of a heterologous bluetongue virus double-strand RNA (ribonucleic acid) endogenous interferon inducer. The inducer is prepared by extracting naked double-strand ribonucleic acid (dsRNA) from animal bluetongue virus, and can be directly applied in a human body to induce the human body to generate endogenous interferon, thereby endowing the human body with the functions of resisting virus, resisting cancer, preventing diseases, treating diseases and enhancing physique. The inducer has the main advantages that: A) the inducer can directly induce the human body to generate various endogenous interferons (ENI), and has high in-vivo concentration, strongest antiviral and anticancer activities, no immunogenicity of heterologous protein, no dependence, no need of purification and low cost; B) the inducer has no infectivity, is dsRNA virus, has no tumor origin, is natural virus and has no influence on ecological balance; C) the inducer is a fully new natural and green biological material, which is safe to human, is never used up, can be regenerated infinitely and is favorable for in-vitro proliferation and purification preparation; and D) the inducer highly meets the species specificity and has a strongest pharmacological action in the human body.

The invention discloses a broad-spectrum and high efficient traditional Chinese medicine interferon inducer composition for treatment for avian viral diseases and a preparation method thereof. The traditional Chinese medicine interferon inducer composition for treatment for avian viral diseases of the invention is composed of components with the parts by weight: 5 to 20 parts of Indian buead, 5 to 20 parts of pilose Asiabell root, 5 to 20 parts of membranous milkvetch root, 5 to 20 parts of baical skullcap root and 20 to 60 parts of golden thread. The preparation method of the invention is as follows: the components are respectively weighed according to the parts by weight and cut into thin segments, clean water is used for normal temperature soaking, after that, the decoction is carried out, impurity-removal, filtration and sterilization are carried out for preparation. The traditional Chinese medicine interferon inducer composition has high purity, strong efficacy and high medicine density, which can also effectively improve the stability of the drug and does not block a nipple drinking fountain; the dosage is reduced and the virus killing function is great.

The invention discloses application of a heterogeneous bluetongue virus double-strand RNA (ribonucleic acid) in the preparation of an inducer as an endogenic interferon. The inducer is prepared by extracting naked dsRNA (double-strand ribonucleic acid) molecules from an animal bluetongue virus, is directly used for a human body, induces the human body to generate the endogenic interferon, and gives an antiviral function, an anticancer function and wide disease prevention and treatment and health invigoration functions to the human body. The application has the main advantages that: (A), the human body is directly induced to generate the ENIs (endogenic interferons) with complete varieties, the in-vivo concentration is high, the antiviral activity and the antitumor activity are strongest, the immunogenicity of a heterogeneous protein is free, the dependence is free, the purification is not necessary, and the manufacturing cost is low; (B), the infectivity is free, the heterogeneous bluetongue virus is a dsRNA virus, the tumor origin is free, the heterogeneous bluetongue virus is a natural virus, and the ecological equilibrium is not influenced; (C), the heterogeneous bluetongue virus is a brand-new natural green biomaterial which is safe to people, is inexhaustible, can be regenerated infinitely, and is convenient for in-vitro proliferation, purification and preparation; and (D), the species specificity is highly accorded, and the pharmacological action in the human body is strongest.

The invention discloses a screening method for a porcine interferon inducer. The screening method comprises the following steps: in-vitro culture of porcine small intestinal cells IPEC-1; culture of acell line IPEC-1/AcGFP1-IFN-beta for stably expressing a green fluorescent protein gene and a porcine interferon beta gene; inoculation of cells IPEC-1/AcGFP1-IFN-beta into a culture plate to form acell climbing plate; use of an inducer to be screened to treat the cells IPEC-1/AcGFP1-IFN-beta to obtain cells to be tested, observation of AcGFP1 fluorescence intensity of the cells to be tested, and screening of the porcine interferon inducer according to the AcGFP1 fluorescence intensity. The screening method for the porcine interferon inducer has the advantages of rapid screening, strong targeting and accurate results, and the selected porcine interferon inducer can be directly used as a feed additive for adding into a feed for piglets to induce production of interferon in bodies of the piglets to achieve the effect of resisting piglet diseases.

The invention relates to a traditional Chinese medicine containing liquorice. The traditional Chinese medicine containing liquorice comprises the following components in parts by weight: 90-100 parts of liquorice, 50-75 parts of dried ginger, 20-50 parts of radix scrophulariae, 50-80 parts of rehmannia root, 15-25 parts of Chinese yam, 20-30 parts of Szechwan lovage rhizome, 25-35 parts of Chinese angelica, 60-80 parts of mannitol and 5-7 parts of talcum powder. The liquorice and the dried ginger are taken as raw materials, hormone or antibiotic component in western medicine is not contained, and drug resistance can not be produced; natural plants are adopted, no obvious toxic or side effect is found in study, the safety is high, and the traditional Chinese medicine containing liquorice is easy to absorb and convenient to use and takes effect quickly; the finished product, namely the traditional Chinese medicine containing liquorice, has the anti-inflammation and antiviral effects and the effects of protecting liver, detoxifying and enhancing immunity. Glycyrrhizic acid has glucocorticoid-like pharmacological action, produces no serious adverse reaction, is widely applied to treatment on various acute and chronic hepatitides, trachitis and Aids in clinical and also has the effects of resisting cancer and preventing cancer and the functions of an interferon inducer and a cellular immunity regulator; the clycyrrhizic acid has the effects of reducing blood fat and preventing atherosclerosis and can be used for preventing formation of atherosclerosis; the traditional Chinese medicine containing liquorice is low in cost and simple in technology and can be widely applied.

The invention discloses a 2-arylureido-N-(4-fluorobenzyl)nicotinamide compound and an application thereof, belongs to the technical field of medicines, and particularly relates to the 2-arylureido-N-(4-fluorobenzyl)nicotinamide compound, a prodrug, a drug active metabolite and a pharmaceutically acceptable salt thereof, and the application thereof as an anti-influenza virus drug; and particularly, the 2-arylureido-N-(4-fluorobenzyl)nicotinamide compound has a relatively good curative effect on various influenza A. The 2-arylureido-N-(4-fluorobenzyl)nicotinamide compound provided by the invention can also be used in combination with known medicaments which can be used for treating or preventing influenza. Preferred combinations comprise the compound provided by the invention and an M2 ion channel protein inhibitor, the compound provided by the invention and a neuraminidase inhibitor, the compound provided by the invention and an interferon inducer, the compound provided by the invention and an antisense oligonucleotide, and the compound provided by the invention and an inosine monophosphate dehydrogenase inhibitor.